Logo image of CINC

CINCOR PHARMA INC (CINC) Stock Analyst Ratings

USA - Nasdaq - NASDAQ:CINC - US17240Y1091 - Common Stock

29.06 USD
-0.14 (-0.48%)
Last: 2/23/2023, 8:00:00 PM
29.25 USD
+0.19 (+0.65%)
After Hours: 2/23/2023, 8:00:00 PM
Buy % Consensus

78

ChartMill assigns a Buy % Consensus number of 78% to CINC. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 39.78. This target is 36.89% above the current price.
CINC was analyzed by 12 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about CINC.
In the previous month the buy percentage consensus was at a similar level.
CINC was analyzed by 12 analysts, which is quite many. So the average rating should be quite meaningful.

Related screens

CINC Historical Analyst RatingsCINC Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -12 -11 -10 -9 -8 -7 -6 -5 -4 -3 -2 -1 0 2 4 6 8 10

Price Target & Forecast

Price Low Median Mean High 29.0630.3031.6239.7855.65 - 4.27% 8.81% 36.89% 91.50%

Related screens

CINC Current Analyst RatingCINC Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 1 2 3 4
Up and Down Grades
Date Firm Action Rating
2023-01-12 Barclays Downgrade Overweight -> Equal-Weight
2023-01-10 Morgan Stanley Maintains Equal-Weight
2022-12-08 Barclays Initiate Overweight
2022-12-07 Barclays Initiate Overweight
2022-11-29 Oppenheimer Downgrade Outperform -> Perform
2022-11-29 Morgan Stanley Downgrade Overweight -> Equal-Weight
2022-10-28 Goldman Sachs Initiate Buy
2022-09-09 Morgan Stanley Maintains Overweight
2022-08-22 Piper Sandler Initiate Overweight
2022-08-09 Morgan Stanley Maintains Overweight
2022-07-21 Oppenheimer Maintains Outperform
2022-07-15 Morgan Stanley Maintains Overweight
2022-02-01 Oppenheimer Initiate Outperform
2022-02-01 Evercore ISI Group Initiate Outperform
2022-02-01 Morgan Stanley Initiate Overweight
2022-02-01 Jefferies Initiate Buy

CINCOR PHARMA INC / CINC FAQ

Can you provide the average price target for CINCOR PHARMA INC stock?

12 analysts have analysed CINC and the average price target is 39.78 USD. This implies a price increase of 36.89% is expected in the next year compared to the current price of 29.06.


How do analysts rate CINCOR PHARMA INC (CINC)?

The consensus rating for CINCOR PHARMA INC (CINC) is 78.3333 / 100 . This indicates that analysts generally have a positive outlook on the stock.


How many analysts have analysed CINCOR PHARMA INC (CINC)?

The number of analysts covering CINCOR PHARMA INC (CINC) is 12.